• Clinical Insights: May 18, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Empaveli™ (pegcetacoplan) Injection – New Drug Approval – May 14, 2021 – Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the U.S.… Read more »

  • Clinical Insights: May 11, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval No new update. New/Updated Drug Shortage May 07, 2021 Azacitidine for Injection (Currently in Shortage) Bumetanide… Read more »

  • Clinical Insights: May 4, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Kloxxado™ (naloxone hydrochloride) Nasal Spray – New Drug Approval – April 30, 2021 – The U.S. Food and Drug Administration announced the approval of a higher dose naloxone hydrochloride… Read more »

  • Clinical Insights: April 27, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Jemperli™ (dostarlimab-gxly) Injection – New Drug Approval – April 22, 2021 – GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Jemperli™ (dostarlimab-gxly), a programmed… Read more »

  • Clinical Insights: April 20, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Nextstellis® (drospirenone and estetrol) Tablets – New Drug Approval – April 16, 2021 – Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are very pleased to announce that the… Read more »

  • Clinical Insights: April 13, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Qelbree™ (viloxazine hydrochloride) Extended Release Capsules – New Drug Approval – April 2, 2021 – Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the… Read more »

  • Clinical Insights: April 6, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Roszet™ (ezetimibe and rosuvastatin) Tablets – New Drug Approval – March 23, 2021 – Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet™… Read more »

  • Clinical Insights: March 30, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Abecma™ (idecabtagene vicleucel) Suspension for Intravenous Infusion – New Drug Approval – March 26, 2021 – Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and… Read more »

  • Clinical Insights: March 23, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Ponvory™ (ponesimod) Tablets – New Drug Approval – March 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA)… Read more »

  • Clinical Insights: March 16, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Fotivda™ (tivozanib) – New Drug Approval – March 10, 2021 – The Food and Drug Administration approved tivozanib (Fotivda™, Aveo Pharmaceuticals, Inc.), a kinase inhibitor, for adult patients… Read more »